Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2030

Conditions
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Interventions
DRUG

Adebrelimab + Apatinib

"Adebrelimab: Administered by intravenous infusion at a fixed dose of 1200 mg. The infusion should be completed within 30-60 minutes, with a maximum duration of 2 hours. The first dose is given on Day 1, with subsequent doses repeated every 3 weeks. Dose adjustments (either up or down) are not allowed during the study. A maximum delay of 9 weeks for treatment is allowed, or treatment may be terminated.~Apatinib: 250 mg, taken orally after meals, once daily, continuously. The investigator may temporarily pause the dose or adjust the administration schedule based on symptomatic treatment, such as changing to an every-other-day (qod) schedule or a 5-day-on, 2-day-off regimen. Once toxicity resolves, treatment may resume at the original dose.~The combined treatment of Adebrelimab + Apatinib for consolidation therapy should not exceed 24 months in total."

Trial Locations (1)

330006

The Second Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors
lead

Second Affiliated Hospital of Nanchang University

OTHER